Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Cancer, Breast|Cancer, Lung|Cancer of Colon|Cancer of Pancreas|Cancer, Ovarian|Lymphoma, Non-Hodgkin
Interventions: DRUG: Receipt of granulocyte-colony stimulating factor
Sponsor: Catherine M. Lockhart
Collaborators: Harvard Pilgrim Health Care|HealthPartners Institute